Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

Published:2015-10-05 Issue:3 Volume:1 Page:157-169
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Samtani Mahesh N.¹,Xu Steven X.¹,Russu Alberto¹,Adedokun Omoniyi J.¹,Lu Ming¹,Ito Kaori²,Corrigan Brian²,Raje Sangeeta²,Brashear H. Robert¹,Styren Scot²,Hu Chuanpu¹

Affiliation:

1. Janssen Research & Development, LLC; NJ USA

2. Pfizer Ltd.; CT USA

Funder

Pfizer

Janssen Alzheimer Immunotherapy Research & Development, LLC

Janssen Research & Development, LLC

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.trci.2015.09.001/fullpdf

Reference31 articles.

1. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A beta regression meta-analysis;Rogers;J Pharmacokinet Pharmacodyn,2012

2. The future is now: Model-based clinical trial design for Alzheimer's disease;Romero;Clin Pharmacol Ther,2015

3. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database;Ito;Alzheimers Dement,2011

4. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative;Samtani;J Clin Pharmacol,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of future dementia among patients with mild cognitive impairment (MCI) by integrating multimodal clinical data;Heliyon;2024-09

2. Prediction of Future Dementia Among Patients with Mild Cognitive Impairment (MCI) by Integrating Multimodal Clinical Data;2024

3. Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?;Frontiers in Pharmacology;2023-06-02

4. Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials;Journal of Pharmacokinetics and Pharmacodynamics;2023-01-04

5. Identification of genetic risk factors based on disease progression derived from longitudinal brain imaging phenotypes;IEEE Transactions on Medical Imaging;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3